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Point-of-care testing for procalcitonin in
identifying bacterial infections in young
infants: a diagnostic accuracy study
Thomas Waterfield1* , Julie-Ann Maney2, Martin Hanna2, Derek Fairley2 and Michael D. Shields1
Abstract
Background: The primary objective of this study was to report on the diagnostic accuracy of point-of-care testing
(POCT) for procalcitonin (PCT) in identifying invasive bacterial infections in young infants. Invasive bacterial infection
was defined as the isolation of a bacterial pathogen in blood or cerebrospinal fluid culture.
Methods: This was a prospective observational diagnostic accuracy study. Young infants less than 90 days of age
presenting to the Royal Belfast Hospital for Sick Children with signs of possible bacterial infection were eligible for
inclusion. Eligible infants underwent point-of-care testing for procalcitonin in the emergency department. Testing
was performed by clinical staff using 0.5 ml of whole blood. Results were available within 20 min.
Results: 126 children were included over a 5-month period between September 2017 and January 2018. There
were 14 children diagnosed with bacterial infections (11.1%). Of these 4 children were diagnosed with invasive
bacterial infections (3.2%). POCT procalcitonin demonstrated an excellent diagnostic accuracy for identifying
children with invasive bacterial infection area under the curve (AUC) of 0.97(95% CI, 0.94 to 1.0). At a cut-off value
of 1.0 ng/ml is highly accurate at identifying infants at risk of invasive bacterial infection with a sensitivity and
specificity of 1.00 and 0.92 respectively.
Conclusions: Point-of-care procalcitonin can be performed quickly in the emergency department and demonstrates
an excellent diagnostic accuracy for the identification of young infants with invasive bacterial infections.
Trial registration: NCT03509727 Retrospectively registered on 26th April 2018.
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Background
Young febrile infants under 3 months of age are typic-
ally treated as a high-risk group for invasive bacterial
infection with many receiving parenteral antibiotics
[1]. Over the last 20 years a number of attempts have
been made to identify those young infants in whom
the risk of invasive bacterial infection is low so that
antibiotics could be safely withheld. These include the
Rochester, Philadelphia, Boston criteria and more re-
cently the Step-By-Step approach [2–5].
In the UK the current standard of practice for the
management of febrile children comes from the National
Institute for Health and Care Excellence (NICE) and the
clinical practice guideline 160 “Fever in under 5s: assess-
ment and initial management” [1]. In that guidance
young febrile infants less than 3 months of age are iden-
tified as high risk of serious bacterial infection; with the
advice that all febrile infants under 1 month of age and
any “unwell” appearing febrile young infants are admin-
istered immediate parenteral antibiotics [1]. The NICE
guidance appropriately advocates a low threshold for
parental antibiotics with the acceptance that some chil-
dren will be treated unnecessarily. This approach reflects
the challenge of recognising early serious bacterial infec-
tion in this group. This necessarily cautious approach
needs balanced with the need for better anti-microbial
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stewardship to prevent the spread of multi-drug resistant
bacteria [6, 7].
There is therefore a need for improved diagnostics to
help better identify those infants requiring immediate
parental antibiotics from those who do not. This has led
to a growing interest in point-of-care testing (POCT) for
biomarkers of infection including procalcitonin (PCT)
[5, 8–14]. In the UK procalcitonin is not routinely used
in the assessment of young febrile infants as it is not
currently recommended by NICE. NICE have however,
called for additional research into the diagnostic accur-
acy of PCT in the assessment of febrile children [1].
At the Royal Belfast Hospital for Sick Children we
introduced point-of-care testing for PCT to specific-
ally help identify invasive bacterial infections in young
infants.
Objectives
The primary objective of this study was to assess the diag-
nostic accuracy of point-of-care testing for PCT in identi-
fying young infants with invasive bacterial infections.
The secondary objective was to determine the diagnos-
tic accuracy of point-of-care testing for PCT in identify-
ing young infants with any bacterial infection (invasive
or non-invasive).
Methods
Study design
The RBHSC is Northern Ireland’s only tertiary paediatric
children’s hospital and has 40,000 attendances to the
emergency department annually. This prospective diag-
nostic accuracy study was conducted from the 1st of
September 2017 until the 31st January 2018.
Case report forms were prospectively completed for all
those undergoing PCT testing. The study was designed
to adhere to the STARD criteria for reporting diagnostic
accuracy studies [15].
Data collection
Anonymised data were collected on standardised case
report forms. Data collected included age, gender,
temperature on arrival, PCT result and final diagnosis
including culture results and molecular testing.
Inclusion criteria
Any child under 90 days of age presenting with signs or
symptoms suggestive of possible bacterial infection. The
NICE guidance CG160 “Fever in under 5s: assessment
and initial management” was used as a guide for clini-
cians (Table 1). Children were included at the discretion
of the attending clinician.
Exclusion criteria
There were no exclusion criteria for this study. Any
child under 90 days of age (uncorrected for gestational
age) with signs of infection as outlined by NICE guid-
ance “Fever in under 5s: assessment and initial manage-
ment” was eligible for inclusion (Table 1).
The broad inclusion and exclusion criteria were
chosen to (i) best reflect current clinical practice in the
UK (ii) to minimise selection bias and (iii) provide clinic-
ally applicable results for clinicians.
Index test
Procalcitonin was tested using the commercially avail-
able, CE marked, BRAHMS procalcitonin assay on the
Samsung LABGEO IB10® analyser in the paediatric
emergency department. All testing was performed by
emergency department staff using 0.5 ml of whole blood
and as per the manufacturer’s instructions. Testing was
performed immediately after collecting the blood sample
and results were available within 20 min. In all instances
the procalcitonin result was available before the refer-
ence standard.
Reference standards
Invasive bacterial infection (IBI) defined as isolation of a
bacterial pathogen in blood or cerebrospinal fluid cul-
ture. Staphylococcus epidermidis and Streptococcus viri-
dans were considered contaminants.
Non-invasive bacterial infections (Non-IBI) defined as:
 Urinary Tract Infection (UTI) – Growth of > 10,0000
cfu/ml of a single organism from either a single
invasive sample (catheter or suprapubic aspiration) or
two non-invasive samples.
 Bacterial gastroenteritis - Isolation of bacteria in stool.
 Pneumonia - Focal consolidation on chest radiograph
confirmed by an experienced paediatric radiologist.
In all instances the technicians performing the refer-
ence standard testing were blinded to the results of the
index tests.
Statistical analysis
Normally distributed data were expressed as mean
(Standard Deviation, SD), non-normally distributed data
as median and interquartile range, and categorical vari-
ables were reported as percentages. We calculated the
sensitivity and specificity of procalcitonin at a range of
pre-determined cut-offs. The area under the receiver op-
erating characteristic (ROC) curves for procalcitonin
were reported for both invasive and all bacterial infec-
tions. Analysis was performed using IBM SPSS Statistics
Version 23.
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Ethical approval
Procalcitonin testing was being introduced as a service
development to improve patient care at the RBHSC. This
service development project was reviewed and approved
by the Belfast Health and Social Care Trust Research and
Development office and no Office for Research Ethics
Committees approval was deemed necessary.
Study registration
This study was retrospectively registered at https://
www.clinicaltrials.gov (trial registration: NCT03509727)
on the 26th April 2018.
Results
A total of 126 children were recruited to the study
including 4 children with IBI (all E. coli bacteraemia)
and 10 children with Non-IBI (all urinary tract infec-
tions). All children had complete demographic and
clinical data sets. The median age at presentation was
42 days and the median temperature at presentation
was 37.4 °C. A summary of the demographic and clin-
ical data is shown in Table 2. A patient flow of re-
sults is shown in Fig. 1.
Fig. 1 Flow Diagram of Study
Table 2 Epidemiological & Clinical Data of Patients
Epidemiological & Clinical Data
Male (%) 51
Female (%) 49
Age (Median and interquartile range), days 42 (14–70)
Median Temperature at Presentation (Median
and interquartile range), °C
37.4 (35.9–38.9)
Parenteral Antibiotics, % 27.8
Invasive Bacterial Infection, % (All E. coli
Bacteraemia)
3.2
Non-invasive Bacterial Infection, % (All Urinary
Tract Infections)
7.9%
Table 1 Signs and symptoms of serious illness as defined by
NICE CG160 – “Fever in under 5s: assessment and initial” [1]
High Risk Features Intermediate Risk Features
Pale/mottled/ashen/blue skin,
lips or tongue
Pallor of skin, lips or tongue
reported by parent or carer
No response to social cues Not responding normally to
social cues
Appearing ill to a healthcare
professional
No smile
Does not wake or if roused
does not stay awake
Wakes only with prolonged
stimulation
Weak, high-pitched or
continuous cry
Decreased activity
Grunting Nasal flaring
Respiratory rate greater than
60 breaths per minute
Dry mucous membranes
Moderate or severe chest
indrawing
Poor feeding in infants
Reduced skin turgor Reduced urine output
Bulging fontanelle. Rigors
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Diagnostic accuracy of procalcitonin testing for bacterial
infections
The area under the curve (AUC) for the receiver operat-
ing characteristic (ROC) curve for identifying infants
with IBI was 0.97(95% CI, 0.94 to 1.00) and the AUC for
identifying infants with all bacterial infections was
0.91(95% CI, 0.78 to 1.00) as shown in Fig. 2. The sensi-
tivity, specificity, negative predictive value (NPV) and
positive predictive value of PCT testing over a range of
cut-offs is shown in Table 3.
Comparison with laboratory CRP testing
Of the 126 patients that underwent PCT testing 121 also
had C-Reactive Protein (CRP) testing performed in the
hospital laboratory. This cohort included all of the chil-
dren with bacterial infections (n = 14). In this cohort
CRP demonstrated an AUC for identifying infants with
IBI of 0.98(95% CI, 0.96 to 1.00) and an AUC for identi-
fying infants with all bacterial infections of 0.98(95% CI,
0.96 to 1.00). The sensitivity, specificity, negative pre-
dictive value (NPV) and positive predictive value of PCT
testing over a range of cut-offs is shown in Table 4.
Discussion
Main findings
This study demonstrates that POCT for PCT is highly
accurate at identifying infants with invasive bacterial in-
fections AUC 0.97. At a cut-off value of 1.0 ng/ml is
highly accurate at identifying infants at risk of invasive
bacterial infection with a sensitivity and specificity of
1.00 and 0.92 respectively.
Fig. 2 Receiver Operating Characteristic (ROC) Curves for Procalcitonin (PCT)
Table 3 Diagnostic Accuracy of PCT point-of-care in Identifying Infants with Bacterial Infections with 95% Confidence Intervals
PCT Cut-off 0.25 ng/ml PCT Cut-off 0.5 ng/ml PCT Cut-off 1.0 ng/ml
Invasive Bacterial
Infection
All Bacterial
Infection
Invasive Bacterial
Infection
All Bacterial
Infection
Invasive Bacterial
Infection
All Bacterial
Infection
Sensitivity 1.00 (0.40 to 1.00) 0.86 (0.56 to 0.97) 1.00 (0.40 to 1.00) 0.86 (0.56 to 0.97) 1.00 (0.40 to 1.00) 0.86 (0.56 to 0.97)
Specificity 0.72 (0.63 to 0.80) 0.77 (0.68 to 0.84) 0.91 (0.84 to 0.95) 0.97 (0.92 to 0.99) 0.92 (0.85 to 0.96) 0.98 (0.93 to 0.99)
Positive Predictive Value 0.11 (0.03 to 0.26) 0.32 (0.18 to 0.49) 0.27 (0.09 to 0.55) 0.80 (0.51 to 0.95) 0.29 (0.10 to 0.58) 0.86 (0.56 to 0.97)
Negative Predictive Value 1.00 (0.95 to 1.00) 0.98 (0.93 to 1.00) 1.00 (0.96 to 1.00) 0.98 (0.93 to 1.00) 1.00 (0.96 to 1.00) 0.98 (0.93 to 1.00)
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In this study it was not possible to directly compare
CRP and PCT due to (i) not all children had both tests
performed and (ii) PCT was performed as a rapid
point-of-care test whereas CRP was performed in the la-
boratory. The available data regarding the diagnostic ac-
curacy of CRP in this study does however, suggest that if
a rapid and reliable point-of-care CRP test was available
it could be expected to perform similarly to that of
point-of-care PCT in this population.
What this adds
Current NICE guidance does not recommend the use of
PCT in the assessment of febrile young infants [1]. This is
despite large scale multicentre research from across Eur-
ope demonstrating the value of PCT testing in this group
[5, 14, 16, 17]. NICE state that “the benefit of adding PCT
to this schedule is not clear”. This study, although small,
demonstrates that POCT procalcitonin testing demon-
strates a high diagnostic accuracy for identifying young in-
fants at risk of bacterial infection in a UK population.
The addition of POCT procalcitonin testing to the ini-
tial assessment of young infants with signs of infection
may improve the early recognition of serious bacterial
infection in this group.
Study limitations and future research
This study is limited in that it was performed over a
short duration in a single centre with small numbers of
infants. Furthermore, infants were included at the dis-
cretion of the attending clinician thereby introducing
potential selection bias. This was unavoidable as PCT
testing was introduced as service development and this
study performed as an observation of routine care.
Despite this the rate of bacterial infection diagnosed
in this study (11.1%) is slightly lower than reports in
other larger studies in Europe and The USA (11.9–
23.1%) suggesting that selection bias towards sicker
children with greater risk of bacterial infection was
unlikely [5, 14, 17–20].
To fully elucidate the value of PCT testing and the
most appropriate cut-off value further multicentre pro-
spective studies are required.
Conclusions
Our data suggests that POCT for procalcitonin demon-
strates an excellent diagnostic accuracy for identifying
young infants with invasive bacterial infections.
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Table 4 Diagnostic Accuracy of Laboratory CRP in Identifying Infants with Bacterial Infections with 95% Confidence Intervals
CRP cut-off 20 mg/l CRP cut-off 50 mg/l CRP cut-off 100 mg/l
Invasive Bacterial
Infection
All Bacterial
Infection
Invasive Bacterial
Infection
All Bacterial
Infection
Invasive Bacterial
Infection
All Bacterial
Infection
Sensitivity 1.00 (0.40 to 1.00) 0.93 (0.64 to 1.00) 1.00 (0.40 to 1.00) 0.62 (0.32 to 0.85) 0.50 (0.01 to 0.91) 0.21 (0.07 to 0.19)
Specificity 0.86 (0.78 to 0.92) 0.94 (0.87 to 0.97) 0.96 (0.89 to 0.98) 0.99 (0.94 to 1.00) 0.99 (0.95 to 1.00) 1.00 (0.96 to 1.00)
Positive Predictive Value 0.20 (0.07 to 0.44) 0.65 (0.41 to 0.84) 0.44 (0.15 to 0.77) 0.89 (0.51 to 0.99) 0.67 (0.13 to 0.98) 1.00 (0.31 to 1.00)
Negative Predictive Value 1.00 (0.95 to 1.00) 0.99 (0.94 to 1.00) 1.00 (0.96 to 1.00) 0.96 (0.9 to 1.00) 0.98 (0.93 to 1.00) 0.91 (0.83 to 0.95)
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